Détail de la revue
The Lancet. Neurology |
Documents disponibles dans cette revue



![]()
Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development
Thompson R, Spendiff S, Roos A, et al.
The Lancet. Neurology, 2020, 19, 6, p 522
Revue : The Lancet. Neurology, 19, 6 Titre : Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development Type de document : Article Auteurs : Thompson R ; Spendiff S ; Roos A ; Bourque PR ; Warman Chardon J ; Kirschner J ; Horvath R ; Lochmuller H Editeur : England Année de publication : 06/2020 Pages : p 522 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32470424 / DOI : 10.1016/S1474-4422(20)30028-4
N° Profil MNM : 2020053 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32470424 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Nusinersen in adults with spinal muscular atrophy: new challenges
Mercuri E, Sansone V
The Lancet. Neurology, 2020, 19, 4, p 283
Revue : The Lancet. Neurology, 19, 4 Titre : Nusinersen in adults with spinal muscular atrophy: new challenges Type de document : Article Auteurs : Mercuri E, Auteur ; Sansone V Editeur : England Année de publication : 04/2020 Pages : p 283 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32199087 / DOI : 10.1016/S1474-4422(20)30068-5
N° Profil MNM : 2020032 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32199087 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Leading the way for neuromuscular disorders since 1950
Collectif
The Lancet. Neurology, 2020, 19, 3, p 195
Revue : The Lancet. Neurology, 19, 3 Titre : Leading the way for neuromuscular disorders since 1950 Type de document : Article Auteurs : Collectif, Auteur Editeur : England Année de publication : 03/2020 Pages : p 195 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32085828 / DOI : 10.1016/S1474-4422(20)30027-2
N° Profil MNM : 2020022 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32085828 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Hagenacker T, Wurster CD, Gunther R, et al.
The Lancet. Neurology, 2020, 19, 4, p 317
Revue : The Lancet. Neurology, 19, 4 Titre : Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study Type de document : Article Auteurs : Hagenacker T, Auteur ; Wurster CD ; Gunther R ; Schreiber-Katz O ; Osmanovic A ; Petri S ; Weiler M ; Ziegler A ; Kuttler J ; Koch JC ; Schneider I ; Wunderlich G ; Schloss N ; Lehmann HC ; Cordts I ; Deschauer M ; Lingor P ; Kamm C ; Stolte B ; Pietruck L ; Totzeck A ; Kizina K ; MÃ nninghoff C ; von Velsen O ; Ose C ; Reichmann H ; Forsting M ; Pechmann A ; Kirschner J ; Ludolph AC ; Hermann A ; Kleinschnitz C Editeur : England Année de publication : 03/2020 Pages : p 317 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32199097 / DOI : 10.1016/S1474-4422(20)30037-5
N° Profil MNM : 2020032 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32199097 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Hanna MG, Badrising UA, Benveniste O, et al.
The Lancet. Neurology, 2019, 18, 9, p 834
Revue : The Lancet. Neurology, 18, 9 Titre : Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial Type de document : Article Auteurs : Hanna MG, Auteur ; Badrising UA ; Benveniste O ; Lloyd TE ; Needham M ; Chinoy H ; Aoki M ; Machado PM ; Liang C ; Reardon KA ; de Visser M ; Ascherman DP ; Barohn RJ ; Dimachkie MM ; Miller JAL ; Kissel JT ; Oskarsson B ; Joyce NC ; van den Bergh P ; Baets J ; De Bleecker JL ; Karam C ; David WS ; Mirabella M ; Nations SP ; Jung HH ; Pegoraro E ; Maggi L ; Rodolico C ; Filosto M ; Shaibani AI ; Sivakumar K ; Goyal NA ; Mori-Yoshimura M ; Yamashita S ; Suzuki N ; Katsuno M ; Murata K ; Nodera H ; Nishino I ; Romano CD ; Williams VSL ; Vissing J ; Auberson LZ ; Wu M ; de Vera A ; Papanicolaou DA ; Amato AA Editeur : England Année de publication : 09/2019 Pages : p 834 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 31397289 / DOI : 10.1016/S1474-4422(19)30200-5
N° Profil MNM : 2019082 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/31397289 Voir aussiAvis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Wolfe GI, Kaminski HJ, Aban IB, et al.
The Lancet. Neurology, 2019, 18, 3, p 259
Permalink![]()
New therapies for neuromuscular diseases in 2018.
Shah AM, Al-Chalabi A
The Lancet. Neurology, 2019, 18, 1, p. 12-13
Permalink![]()
Endpoint choice for inclusion body myositis: a step too far?
Schmidt J
The Lancet. Neurology, 2019, 18, 9, p 807
Permalink![]()
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.
Grunseich C, Miller R, Swan T, et al.
The Lancet. Neurology, 2018, 1043-1052
Permalink![]()
Classification and management of adult inflammatory myopathies
Selva-O'Callaghan A, Pinal-Fernández I, Trallero-Araguas E, et al.
The Lancet. Neurology, 2018, 17, 9, p 816
Permalink![]()
Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial
Okkersen K, Jimenez-Moreno C, Wenninger S, et al.
The Lancet. Neurology, 2018
Permalink![]()
Myotonic dystrophy type 1: reasons to be OPTIMISTIC
Gagnon C, Gallais B, Laberge L
The Lancet. Neurology, 2018
Permalink![]()
Neuromuscular disorders : 2017, a year to remember
Mercuri E
The Lancet. Neurology, 2018, 17, 1, p 12
Permalink![]()
IGF-1 for spinal and bulbar muscular atrophy: hope and challenges
Hashizume A, Hashizume A, Katsuno M
The Lancet. Neurology, 2018, 17, 12, p 1026
Permalink![]()
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
Birnkrant DJ, Bushby K, Bann CM, et al.
The Lancet. Neurology, 2018, 17, 3, p 251
Permalink![]()
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
Birnkrant DJ, Bushby K, Bann CM, et al.
The Lancet. Neurology, 2018, 17, 4, p 347
Permalink![]()
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
Birnkrant DJ, Bushby K, Bann CM, et al.
The Lancet. Neurology, 2018, 17, 5, p 445
Permalink![]()
Evidence-based care in Duchenne muscular dystrophy
McDonald CM, Mercuri E
The Lancet. Neurology, 2018, 17, 5, p 389
Permalink![]()
Genetic therapies for spinal muscular atrophy type 1
Aartsma-Rus A, Aartsma-Rus A
The Lancet. Neurology, 2017
Permalink![]()
Neuromuscular diseases: hope and hurdles in clinical trials
Verschuuren JJ, Verschuuren JJ
The Lancet. Neurology, 2017, 16, 1, p 12
Permalink![]()
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
Howard JF, Jr., Utsugisawa K, Benatar M, et al.
The Lancet. Neurology, 2017, 16, 12, p 976
Permalink![]()
Stakeholder collaboration for spinal muscular atrophy therapy development
Aartsma-Rus A, Balabanov P, Binetti L, et al.
The Lancet. Neurology, 2017, 16, 4, p 264
Permalink![]()
Another milestone in childhood spinal muscular atrophy
Wokke JH
The Lancet. Neurology, 2017, 16, 7, p 491
Permalink![]()
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, et al.
The Lancet. Neurology, 2017, 16, 7, p 513
Permalink![]()
Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial
Tardieu M, Zérah M, Gougeon ML, et al.
The Lancet. Neurology, 2017, 16, 9, p 712
Permalink